Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Metastatic Solid Tumors with ARID1A Mutation
NCT04957615Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate up to 2 years and Overall Survival up to 2 years. Started Sep 2021; status: active, not recruiting.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04957615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04957615.